- Conditions
- Mild Cognitive Impairment, Mild to Moderate Cognitive Impairment
- Interventions
- spectral-domain optical coherence tomography (SD-OCT)
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 34
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Hypertension,Essential, Retinal Vascular Disorder
- Interventions
- Swept-Source (SS) OCT Angiography, Spectral-Domain (SD) OCT Angiography, Fundus Imaging, Axial Length Measurement Device
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,050 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Normal Eyes and Eyes With Ocular Pathologies
- Interventions
- SD-OCT
- Device
- Lead sponsor
- Optovue
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Newark, New Jersey • Marysville, Ohio
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Frontotemporal Dementia
- Interventions
- Spectral-Domain Optical Coherence Tomography (SD-OCT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Comprehensive Ophthalmic Examination, Fundus Photography
- Device · Diagnostic Test
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Normal Eyes and Ocular Pathology
- Interventions
- SD-OCT
- Device
- Lead sponsor
- Optovue
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Marysville, Ohio
- Conditions
- Glaucoma
- Interventions
- SDOCT-GMPE software
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Retinal Vein Occlusion
- Interventions
- Dexamethasone intravitreal implant, Monthly Ranibizumab
- Drug
- Lead sponsor
- Brian Burke, MPH
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Interventions
- Dorzolamide-timolol
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Uveitis, Macular Edema
- Interventions
- Dexamethasone intravitreal implant 0.7 mg, Intravitreal Methotrexate 400 µg, Intravitreal Ranibizumab 0.5 mg
- Drug
- Lead sponsor
- JHSPH Center for Clinical Trials
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
- Conditions
- Radiation Retinopathy
- Interventions
- 0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP)
- Drug · Procedure
- Lead sponsor
- Greater Houston Retina Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 4
- States / cities
- Dallas, Texas • Houston, Texas • Katy, Texas + 1 more